Loading organizations...
InnoBio is a venture capital firm specializing in early-stage equity investments within the life sciences sector, focusing on biotech and healthcare companies developing innovative therapies and products from discovery through clinical proof of concept. The firm manages significant capital, with its InnoBio 2 vehicle achieving a first closing of €135 million, following its predecessor InnoBio fund which raised €139 million, totaling over €274 million across both funds. Its limited partners comprise prominent pharmaceutical companies such as Sanofi, Boehringer Ingelheim, Takeda, Ipsen, and Servier, alongside government entities like BpiFrance. InnoBio actively supports its portfolio companies, which include ImCheck Therapeutics, Ona Therapeutics, and Poxel, through various development stages. While specific founding details are not publicly available, the firm's second fund, InnoBio 2, was actively deploying capital into new investments as of 2020.
InnoBio has 5 tracked investments across 5 companies. The latest tracked deal is $47.0M Series B in ENYO Pharma in June 2018.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2018 | ENYO Pharma | $47.0M Series B | OrbiMed | Andera Partners, Earlybird Venture Capital, Kurma Partners, Pfizer Venture Investments, Pureos Bioventures, SR ONE, Third Rock Ventures, Wellington Partners, Vincent Brichard, Bpifrance, Inserm Transfert Initiative, Morningside, Sofinnova Investments |
| Dec 16, 2015 | GamaMabs Pharma | $16.4M Series B | — | Alto Invest, IRDInov, IXO Private Equity |
| Sep 9, 2015 | Biom'Up | $34.9M Series C | — | Laurent Higueret, Euroainvest, Karl Nagler, L'améliane, Casper Breum, Merieux Equity Partners, OTC AM, Sham, Sofimac, Viveris Management |
| Apr 9, 2013 | Medday Pharmaceuticals | $10.5M Other Equity | — | Sofinnova Partners |
| Dec 21, 2012 | Poxel | $17.1M Series B | — | Omnes Capital |
